$725.28
-20.41[-2.74%]
At close: Apr 24
$725.28
0[0.00%]
After Hours: 7:10PM EDT
Eli Lilly and Co
(NYSE:LLY)Eli Lilly and Co Stock (NYSE:LLY), Analyst Ratings, Price Targets, Predictions
Eli Lilly and Co has a consensus price target of $639.37, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Cantor Fitzgerald, and Goldman Sachs on April 18, 2024, April 15, 2024, and April 11, 2024. With an average price target of $784.33 between Cantor Fitzgerald, Cantor Fitzgerald, and Goldman Sachs, there's an implied 8.14% upside for Eli Lilly and Co from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Goldman Sachs
Erste Group
Citigroup
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Eli Lilly and Co
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 12.37% | Cantor Fitzgerald | Louise Chen | → $815 | Reiterates | Overweight → Overweight | Get Alert |
| 04/15/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 12.37% | Cantor Fitzgerald | Louise Chen | → $815 | Reiterates | Overweight → Overweight | Get Alert |
| 04/11/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | -0.31% | Goldman Sachs | Chris Shibutani | $650 → $723 | Maintains | Neutral | Get Alert |
| 04/05/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 12.37% | Cantor Fitzgerald | Louise Chen | → $815 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | — | Erste Group | Hans Engel | — | Upgrade | Hold → Buy | Get Alert |
| 04/02/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 23.4% | Citigroup | Andrew Baum | $675 → $895 | Maintains | Buy | Get Alert |
| 04/01/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 12.37% | Cantor Fitzgerald | Louise Chen | → $815 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 17.2% | Truist Securities | Robyn Karnauskas | → $850 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 17.2% | JP Morgan | Chris Schott | $775 → $850 | Maintains | Overweight | Get Alert |
| 03/01/2024 | LLY | Buy Now | Eli Lilly and Co | $725.28 | 37.88% | B of A Securities | Geoff Meacham | $800 → $1000 | Maintains | Buy | Get Alert |
| 02/21/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 13.06% | DZ Bank | Elmar Kraus | → $820 | Downgrade | Buy → Hold | Get Alert |
| 02/20/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 12.37% | Cantor Fitzgerald | Louise Chen | → $815 | Reiterates | Overweight → Overweight | Get Alert |
| 02/16/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 30.98% | Morgan Stanley | Terence Flynn | $805 → $950 | Maintains | Overweight | Get Alert |
| 02/14/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 12.37% | Cantor Fitzgerald | Louise Chen | → $815 | Reiterates | Overweight → Overweight | Get Alert |
| 02/07/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 17.2% | Truist Securities | Robyn Karnauskas | $650 → $850 | Maintains | Buy | Get Alert |
| 02/07/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 10.99% | Morgan Stanley | David Phung | $763 → $805 | Maintains | Overweight | Get Alert |
| 02/07/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 11.68% | Barclays | Geoff Meacham | $680 → $810 | Maintains | Overweight | Get Alert |
| 02/07/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 13.75% | Wells Fargo | Mohit Bansal | $700 → $825 | Maintains | Overweight | Get Alert |
| 02/07/2024 | LLY | Buy Now | Eli Lilly | $725.28 | 19.26% | BMO Capital | Evan Seigerman | $710 → $865 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Eli Lilly and Co (LLY)?
The latest price target for Eli Lilly and Co (NYSE: LLY) was reported by Cantor Fitzgerald on April 18, 2024. The analyst firm set a price target for $815.00 expecting LLY to rise to within 12 months (a possible 12.37% upside). 85 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Eli Lilly and Co (LLY)?
The latest analyst rating for Eli Lilly and Co (NYSE: LLY) was provided by Cantor Fitzgerald, and Eli Lilly and Co reiterated their overweight rating.
When was the last upgrade for Eli Lilly and Co (LLY)?
The last upgrade for Eli Lilly and Co happened on April 3, 2024 when Erste Group raised their price target to N/A. Erste Group previously had a hold for Eli Lilly and Co.
When was the last downgrade for Eli Lilly and Co (LLY)?
The last downgrade for Eli Lilly and Co happened on February 21, 2024 when DZ Bank changed their price target from N/A to $820 for Eli Lilly and Co.
When is the next analyst rating going to be posted or updated for Eli Lilly and Co (LLY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eli Lilly and Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eli Lilly and Co was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating Eli Lilly and Co (LLY) correct?
While ratings are subjective and will change, the latest Eli Lilly and Co (LLY) rating was a reiterated with a price target of $0.00 to $815.00. The current price Eli Lilly and Co (LLY) is trading at is $725.28, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.